Wang Chao, Chen Lin-Yi, Lu Qing-Bin, Cui Fuqiang
Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
Global Center for Infectious Disease and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing 100191, China.
Vaccines (Basel). 2022 Jun 9;10(6):920. doi: 10.3390/vaccines10060920.
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic. As one of the two inactivated severe acute respiratory syndrome virus 2 (SARS-CoV-2) vaccines developed in China that entered the WHO emergency use list, Sinopharm BBIBP-CorV, an aluminum-hydroxide-adjuvanted, inactivated whole-virus vaccine, has been widely distributed, with more than 400 million doses administered in more than 40 countries. The evidence of the safety, efficacy, and effectiveness of BBIBP-CorV is gathered and reviewed. We further comment on one of the latest papers that disclosed the effectiveness results between BBIBP-CorV, rAd26-rAd5, and ChAdOx1.
2019冠状病毒病（COVID-19）疫苗接种已成为一项重要的公共卫生解决方案。研发一种安全有效的COVID-19疫苗是控制这一疫情的可行长期解决方案。作为中国研发的两种进入世界卫生组织紧急使用清单的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）灭活疫苗之一，国药集团中国生物北京生物制品研究所有限责任公司的新型冠状病毒灭活疫苗（Vero细胞），一种氢氧化铝佐剂的全病毒灭活疫苗，已广泛分发，在40多个国家接种超过4亿剂。收集并审查了新型冠状病毒灭活疫苗（Vero细胞）安全性、有效性和效力的证据。我们进一步对披露新型冠状病毒灭活疫苗（Vero细胞）、重组腺病毒载体疫苗（Ad26.COV2.S）和牛津阿斯利康疫苗（ChAdOx1 nCoV-19）有效性结果的最新论文之一发表评论。
